Can a biological graft improve dialysis access?

NCT ID NCT07773051

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This trial is testing whether a new biological vascular graft, called LineMatrix, is as safe and effective as a standard graft for creating dialysis access in people with end-stage kidney disease. Participants will be randomly assigned to receive either the new graft or the standard one. The study will track how well the grafts stay open and function over 12 months, aiming to see if the new option can offer a reliable alternative for those who cannot use their own blood vessels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LineMatrix® Biological Vascular Graft
What this could lead to
If successful, this could provide a safer, more effective option for creating dialysis access in people with kidney failure who cannot use their own blood vessels.
What could go wrong
This is an early-stage trial, and the new graft may not perform as well as the standard one. There are also risks of clotting or infection, as with any vascular access procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIOVENOUS GRAFT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Haidian Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Longhua Hospital Shanghai University of Traditional Chinese Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

  • South China Hospital of Shenzhen University

    RECRUITING

    Shenzhen, Guangdong, China

  • The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi’an, Shanxi, China

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, China

  • The First Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Hebei, China

  • The Second Affiliated Hospital of Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, China

  • Tongji Hospital Affiliated to Tongji Medical Collage of Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.